Q1 2026 Novocure Ltd Earnings Call Transcript
Key Points
- NovoCure Ltd (NVCR) reported double-digit growth in both active patients and net revenues year-over-year for Q1 2026.
- The launch of Optune Pax for pancreatic cancer is off to a promising start, with positive physician feedback and significant early adoption.
- NovoCure Ltd (NVCR) received FDA approval for Optune Pax and certified 868 healthcare providers within seven weeks of approval.
- The company reported a gross margin increase to 78% in Q1 2026, up from 75% in Q1 2025, driven by lower costs for arrays.
- NovoCure Ltd (NVCR) secured its first major payer coverage policy for Optune Pax with Elevance Health, covering over 30 million lives.
- NovoCure Ltd (NVCR) reported a net loss of $71 million for Q1 2026, compared to $34 million in Q1 2025.
- The company incurred a $43 million share-based compensation charge triggered by the approval of Optune Pax.
- Research and development costs increased by 8% year-over-year, driven by increased costs associated with the KEYNOTE-D58 trial.
- Sales and marketing expenses rose by 5% from Q1 2025, due to launch costs for Optune Pax in the US and Optune Lua in Japan.
- NovoCure Ltd (NVCR) is still in the early stages of understanding the Optune Pax adoption curve and reimbursement dynamics.
Good day, and thank you for standing by. Welcome to the NovoCure's Q1 2026 earnings call. (Operator Instructions) Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Adam Daney. Please go ahead.
Good morning, and thank you for joining us to review NovoCure's first quarter 2026 financial performance. I'm joined on the phone today with our Executive Chairman, Bill Doyle; CEO, Frank Leonard; Chief Innovation and Medical Officer, Uri Weinberg; and CFO, Christoph Brackmann. Other members of our executive leadership team will be available for Q&A.
For your reference, slides accompanying this earnings release can be found on our website, novacure.com on the Investor Relations page under quarterly reports. Before we start, I would like to remind you that our discussions during this conference call will include forward-looking statements, and actual results could differ materially from those projected in these statements.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
